ClinicalTrials.gg
Active, not recruitingNCT02014415Updated Apr 27, 2026

Alpha-1 Antitrypsin Deficiency Adult Liver Study

An observational study in Alpha-1 Antitrypsin Deficiency, sponsored by St. Louis University. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by St. Louis University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Planned enrollment
16th of 26
120 · median 190
Started
2013
with 4 others
Observational
26 of 81
8 open now
Primary completion
2027-12
later than 5 of 20 live
Registered
38th of 81
by date

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 16th largest by planned enrollment of the 26 observational ones that give a count, is one of 5 that started in 2013, is one of 26 observational ones, reaches primary completion later than 5 of the 20 other live ones, and was the 38th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

The investigators hypothesize that there is liver injury (inflammation, fibrosis, cirrhosis) in adults with Alpha-1 Antitrypsin Deficiency (AATD), which is asymptomatic, under-recognized, and undiagnosed. In addition, the investigators believe that the genetic and environmental factors that play an important role in the development of alpha-1 antitrypsin (AAT) liver disease, can be identified by comparing a cohort database of clinical disease information to linked biospecimen and DNA samples.

Read the detailed description

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder resulting in a low level of a protein called alpha-1 antitrypsin (AAT). This deficiency can cause life-threatening liver disease and/or lung disease at various ages. Some patients experience life-threatening liver disease in childhood or liver cancer as adults. There is no specific treatment for AAT related liver disease. Some patients develop emphysema as young adults, while some patients remain healthy throughout their lives. Differences in the environment or in other genes may explain such inconsistency in the disease.

The primary objective of this multi-center study is to assess the natural history of individuals with Pi-ZZ AAT deficiency, identify biomarkers for the progression of liver disease and construct a database capable of linking cohort data with repository biospecimens. The secondary objective is to analyze components of the demographic, social, and family history associated with more severe liver disease.

This study will examine the natural history of liver disease by recording participant's family history, medical history, current health, laboratory test results, and medical treatment(s). Participants may complete brief research questionnaires about their physical and mental health, diet, alcohol intake, and smoke, environmental and occupational (work) exposures.

At least 120 Pi-ZZ AAT deficient adults with no previous history of liver disease, moderate-severe liver disease, or post liver transplant, will be enrolled at one of three sites. Eligible subjects will participate in one of the following study arms:

  1. Liver Biopsy
  2. Known Severe Liver Disease - subjects not meeting Biopsy Group eligibility due to the presence of advanced liver disease
  3. Post Liver Transplant - subjects who have previously undergone a liver transplant

At the time of enrollment, each participant will be assigned a unique study identification (ID) number. All participant information recorded and samples collected for the study will be saved by this unique number. All blood, tissue and genetic samples collected will be sent to a secured repository for future retrieval and study. The process of coding data and samples lessens the chances of a breach in confidentiality.

The length of study participation, tests and activities performed specifically for research will be determined by the enrollment group. Subjects in the Biopsy and Known Severe Liver Disease groups participate in the study for 5 years (enrollment and four annual follow-up visits). Both groups undergo a physical exam, diagnostic abdominal ultrasound, pulmonary function testing and the collection of serum, plasma and blood for routine laboratory and genetic testing (Induced Pluripotent Stem Cells (iPS cells), microRNA and DNA). However, only the Biopsy Group participants undergo a liver biopsy and FibroScan at enrollment, and again in Year 5. The liver tissue samples will help the researchers learn what causes liver disease in some patients and how the liver disease progresses.

Subjects in the Post Liver Transplant group have a single study visit to record their history, complete questionnaires and perform pulmonary function testing. In addition, whole blood for DNA analysis will be collected from these participants.

Based on their study arm assignment, participants will receive copies of their diagnostic abdominal ultrasound, pulmonary function test, routine laboratory test and liver biopsy pathology results, to share with their primary care physician.

Upon completion of the 5-year study, two cross-sectional visits were added to the Biopsy Group and Known Severe Liver Disease Group. The cross-sectional visit will be completed by phone and review of medical records.

03

Conditions studied

  • Alpha-1 Antitrypsin Deficiency

Keywords

  • Alpha-1
  • AAT Deficiency
  • AATD
  • Liver
  • Fibrosis
  • Liver Transplant
  • Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pi-ZZ AAT deficient adults with either no previous history of liver disease, moderate-severe liver disease or post liver transplant. Biologic family members who are also Pi-ZZ and ≥ 18 years of age, will be offered enrollment into the study. The purpose of including family members is to determine if the natural history of the liver disease is consistent in a given family.

Eligibility criteria

Liver Group:

Inclusion Criteria

  • Adults (≥ 18 years of age), with Alpha-1 Antitrypsin Deficiency
  • Documented evidence Pi-ZZ phenotype or genotype
  • Both genders, all races and ethnic groups
  • Willingness to be followed for up to 5 years

Exclusion Criteria:

  • Evidence of advanced liver disease defined by Class B or C (score ≥ 7)
  • Known advanced lung disease defined as forced expiratory volume at one second () \< 40 % of Predicted
  • History of Organ Transplantation
  • Known congenital or metabolic liver disease (e.g.: Wilson's, glycogen storage, cystic fibrosis)or iron overload as evidenced by ≥ Grade 3 iron staining on a previous liver biopsy
  • Evidence of chronic (marked by the presence of HBsAg in serum) or (marked by the presence of anti-hepatitis C virus (HCV) or HCV RNA in serum)
  • Vascular disorders of the liver (e.g.: cardiac sclerosis, acute or chronic Budd-Chiari, hepatoportal sclerosis, peliosis)
  • Known positivity
  • Diagnosis of within the last 5 years
  • Active substance abuse, that in the opinion of the study investigator, would interfere with adherence to study requirements
  • Concomitant severe underlying systemic illness or medical condition which in the opinion of the investigator, would make the patient unsuitable for the study or would interfere with completion of follow-up
  • Inability to comply with the longitudinal follow-up as outlined in the protocol
  • Failure of the participant to sign or Health Insurance Portability and Accountability Act (HIPAA) documents

Known Severe Liver Disease Group:

Inclusion Criteria

  • Adults (≥ 18 years of age), with alpha-1-antitrypsin deficiency
  • Documented evidence PI-ZZ phenotype or genotype
  • Documented evidence of portal hypertension or evidence of advanced liver disease defined by Child-Pugh Class B or C (score ≥ 7), or previous liver biopsy with an Ishak Fibrosis Score ≥ 4
  • Both genders, all races and ethnic groups
  • Willingness to be followed for up to 5 years

Exclusion Criteria

  • History of Organ Transplantation
  • Known congenital or metabolic liver disease (e.g.: Wilson's, glycogen storage, cystic fibrosis) and iron overload as evidenced by ≥ Grade 3 iron staining on a previous liver biopsy
  • Evidence of chronic hepatitis B (marked by the presence of HBsAg in serum) or Hepatitis C (marked by the presence of anti-HCV or HCV RNA in serum)
  • Vascular disorders of the liver (e.g.: cardiac sclerosis, acute or chronic Budd-Chiari, hepatoportal sclerosis, peliosis)
  • Known HIV positivity
  • Diagnosis of malignancy within the last 5 years which in the opinion of the investigator, would make the patient's follow-up problematic or the results uninterpretable.
  • Active substance abuse, that in the opinion of the study investigator, would interfere with adherence to study requirements
  • Concomitant severe underlying systemic illness or medical condition which in the opinion of the investigator, would make the patient unsuitable for the study or would interfere with completion of follow-up
  • Inability to comply with the longitudinal follow-up as outlined in the protocol
  • Failure of the participant to sign informed consent or HIPAA documents.

Post Liver Transplant Group

Inclusion Criteria

  • Adults (≥ 18 years of age), with alpha-1-antitrypsin deficiency
  • Pre-transplant documented evidence of PI-ZZ phenotype or genotype
  • Documented evidence of liver transplantation
  • Both genders, all races and ethnic groups

Exclusion Criteria

  • Active substance abuse, that in the opinion of the study investigator, would interfere with adherence to study requirements
  • Concomitant severe underlying systemic illness or medical condition which in the opinion of the investigator, would make the patient unsuitable for the study or would interfere with completion of study requirements
  • Failure of the participant to sign informed consent or HIPAA documents.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Target follow-up
7 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Liver Biopsy

    Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.

    Procedure: Liver Biopsy (Biopsy Group Only)

  • Known Severe Liver Disease

    Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.

  • Post Liver Transplant

    Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.

Interventions

  • ProcedureLiver Biopsy (Biopsy Group Only)

    A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.

06

What researchers measure

Primary outcomes

  1. The risk and rate of histologic liver injury progression, as measured by liver biopsy, over a 5-year period.

    Time frame: Liver biopsy performed in Year 1 and Year 5

Secondary outcomes

  1. Calculated Model for End-stage Liver Disease score (MELD)

    Time frame: Calculated at baseline and annually through year 5

  2. Liver synthetic dysfunction defined by international normalized ratio (INR) > 1.3 or serum albumin < 3.2 gm/dL

    Time frame: Measured at baseline and annually through year 5

  3. Presence of ascites (or treatment for ascites)

    Time frame: Assessed at baseline and annually through year 5

  4. Development of complications of portal hypertension (e.g., variceal hemorrhage)

    Time frame: Assessed at baseline and annually through year 5

  5. Jaundice (total serum bilirubin >2.0 mg/dl)

    Time frame: Measured at baseline and annually through year 5

  6. Liver transplantation

    Time frame: Assessed annually through year 5

  7. Listing for liver transplantation

    Time frame: Assessed at baseline and annually through year 5

  8. Health related quality of life

    Time frame: Measured at baseline and annually through year 5

  9. FEV1 % of Predicted

    Time frame: Collected at baseline and annually through year 5

  10. Death

    Time frame: Collected annually through year 5

07

Study locations

3 sites
08

References and documents

Publications

  • Suri A, Zhang Z, Neuschwander-Tetri B, Lomas DA, Heyer-Chauhan N, Burling K, Loomba R, Brenner DA, Nagy R, Wilson A, Carpenter D, Blomenkamp K, Teckman J. Fibrosis, biomarkers and liver biopsy in AAT deficiency and relation to liver Z protein polymer accumulation. Liver Int. 2024 Dec;44(12):3204-3213. doi: 10.1111/liv.16094. Epub 2024 Sep 12. PubMed 39263815 ↗

Individual participant data

Plan to share: Yes — Based on study group assignment, participants will be given a copy of their test results as follows: Liver Biopsy Group- liver biopsy pathology, diagnostic abdominal ultrasound, pulmonary function testing, and routine clinical laboratory testing. Known Severe Liver Disease Group- diagnostic abdominal ultrasound, pulmonary function testing, and routine clinical laboratory testing. Post Liver Transplant Group- pulmonary function testing.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Dec 2027 and a completion of Dec 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2013
First posted
Dec 18, 2013
Start
Dec 2013
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02014415
Collaborators
Alpha-1 Foundation, University of California, Boston University, University College, London, University of Massachusetts, Worcester
Responsible party
Jeffrey Teckman M.D. (Professor of Pediatrics and Professor of Biochemistry and Molecular Biology, St. Louis University) — Principal investigator
First posted
Dec 18, 2013
Start date
Dec 2013
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 27, 2026

Study contacts

Jeffrey Teckman, MD
study chair · St. Louis University
Andrew A Wilson, MD
study director · Alpha-1 Foundation
David A. Brenner, MD
principal investigator · The University of California, San Diego
Andrew A Wilson, MD
principal investigator · Boston University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion